Le Lézard
Classified in: Health
Subject: RCL

Food Recall Warning - Maple Dale Cheese Co. brand 1 year old Cheddar recalled due to Listeria monocytogenes


Product photo is available:  https://recalls-rappels.canada.ca/en/alert-recall/maple-dale-cheese-co-brand-1-year-old-cheddar-recalled-due-listeria-monocytogenes

OTTAWA, ON, Feb. 18, 2023 /CNW/ -

Summary
Affected products

Brand

Product     

Size

UPC                     

Codes

Maple Dale
Cheese Co.   

1 year old
cheddar

235 g   

6 23164 22235 6

VAT# 211227 BEST BEFORE 23AU21   ;

VAT# 211197 BEST BEFORE 23AU21 

Issue

The affected product is being recalled from the marketplace due to possible Listeria  contamination.

The recalled product has been sold in Ontario.

What you should do

Food contaminated with Listeria monocytogenes may not look or smell spoiled but can still make you sick. Symptoms can include vomiting, nausea, persistent fever, muscle aches, severe headache and neck stiffness. Pregnant women, the elderly and people with weakened immune systems are particularly at risk. Although infected pregnant women may experience only mild, flu-like symptoms, the infection can lead to premature delivery, infection of the newborn or even stillbirth. In severe cases of illness, people may die.

Learn more:

Background

This recall was triggered by the company.

There have been no reported illnesses associated with the consumption of this product.

What is being done

The Canadian Food Inspection Agency (CFIA) is conducting a food safety investigation, which may lead to the recall of other products.

The CFIA is verifying that industry is removing recalled products from the marketplace.

SOURCE Canadian Food Inspection Agency (CFIA)


These press releases may also interest you

at 03:20
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...

at 03:00
Global biotechnology leader CSL Behring today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the...

at 02:30
SOPHiA GENETICS , a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced that Dhiti Omics Technologies, a precision molecular diagnostics service provider in India, is live on the SOPHiA...

at 01:15
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the Phase II/III SKYSCRAPER-06 study, evaluating tiragolumab plus Tecentriq® (atezolizumab) and chemotherapy versus pembrolizumab and chemotherapy as an initial...

at 01:05
BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, announces the appointment of Deutsche Numis as the Company's Financial and Capital Markets Adviser,...

3 jui 2024
YOUR LEGAL RIGHTS MAY BE AFFECTED There is a proposed settlement in a class-action lawsuit filed against Pfizer Inc., Pfizer Ireland Pharmaceuticals, Warner-Lambert Company, and Warner-Lambert Company LLC (collectively, "Pfizer") and Ranbaxy Inc.,...



News published on and distributed by: